Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: Three peas in a pod? - analysis from a multicenter cross sectional study
Solheim T, Blum D, Fayers P, Hjermstad M, Stene G, Strasser F, Kaasa S. Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: Three peas in a pod? - analysis from a multicenter cross sectional study. Acta Oncol 2013
Sep 2, 2013Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: Three peas in a pod? - analysis from a multicenter cross sectional study
Sep 2, 2013Acta Oncol 2013
Solheim Tora S, Blum David, Fayers Peter M, Hjermstad Marianne J, Stene Guro B, Strasser Florian, Kaasa Stein
Outcome following laparoscopic and open total mesorectal excision for rectal cancer (Br J Surg 2013; 100: 1368-1375)
Gueller U. Outcome following laparoscopic and open total mesorectal excision for rectal cancer (Br J Surg 2013; 100: 1368-1375). Br J Surg 2013; 100:1375-6.
Sep 1, 2013Outcome following laparoscopic and open total mesorectal excision for rectal cancer (Br J Surg 2013; 100: 1368-1375)
Sep 1, 2013Br J Surg 2013; 100:1375-6
Gueller Ulrich
Religionen sind eine existenzielle Antwort - doch worauf?
Renz M. Religionen sind eine existenzielle Antwort - doch worauf?. Neue Zürcher Zeitung 2013:23.
Aug 29, 2013Religionen sind eine existenzielle Antwort - doch worauf?
Aug 29, 2013Neue Zürcher Zeitung 2013:23
Renz Monika
Prospective cost-effectiveness analysis of genomic profiling in breast cancer
Retèl V, Joore M, Drukker C, Bueno-de-Mesquita J, Knauer M, van Tinteren H, Linn S, van Harten W. Prospective cost-effectiveness analysis of genomic profiling in breast cancer. Eur J Cancer 2013; 49:3773-9.
Aug 27, 2013Prospective cost-effectiveness analysis of genomic profiling in breast cancer
Aug 27, 2013Eur J Cancer 2013; 49:3773-9
Retèl V P, Joore M A, Drukker C A, Bueno-de-Mesquita J M, Knauer Michael, van Tinteren H, Linn S C, van Harten W H
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
von Minckwitz G, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Lück H, Müller V, Kreienberg R, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel I, Elling D, Conrad B, Loibl S. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31:3531-9.
Aug 26, 2013German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
Aug 26, 2013J Clin Oncol 2013; 31:3531-9
von Minckwitz Gunter, Bauerfeind Ingo, Clemens Michael, Schmidt Marcus, Noeding Stefanie, Forstbauer Helmut, Barinoff Jana, Belau Antje, Nekljudova Valentina, Harbeck Nadia, Lück Hans-Joachim, Müller Volkmar, Kreienberg Rolf, Möbus Volker, Schneeweiss Andreas, Huober Jens, Thomssen Christoph, Untch Michael, Jackisch Christian, Diel Ingo J, Elling Dirk, Conrad Bettina, Loibl Sibylle
The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients
Clough-Gorr K, Noti L, Brauchli P, Cathomas R, Fried M, Roberts G, Stuck A, Hitz F, Mey U. The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients. BMC Med Inform Decis Mak 2013; 13:93.
Aug 23, 2013The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients
Aug 23, 2013BMC Med Inform Decis Mak 2013; 13:93
Clough-Gorr Kerri M, Noti Lea, Brauchli Peter, Cathomas Richard, Fried Marius R, Roberts Gillian, Stuck Andreas E, Hitz Felicitas, Mey Ulrich
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
Denkert C, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer J, Budczies J, Mehta K, Fehm T, Huober J, Loibl S, Müller B, Eidtmann H, Schmitt W, Eiermann W, Gerber B, Tesch H, Hilfrich J, von Minckwitz G. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013; 24:2786-93.
Aug 22, 2013Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
Aug 22, 2013Ann Oncol 2013; 24:2786-93
Denkert C, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer J U, Budczies J, Mehta K M, Fehm T, Huober Jens, Loibl S, Müller B M, Eidtmann H, Schmitt W D, Eiermann W, Gerber B, Tesch H, Hilfrich J, von Minckwitz G
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br J Cancer 2013; 109:1079-84.
Aug 8, 2013Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
Aug 8, 2013Br J Cancer 2013; 109:1079-84
Omlin Aurelius, de Bono J S, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C J, Attard G
Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss
Zaman K, Thürlimann B, Aebi S. Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss. J Clin Oncol 2013; 31:3440-1.
Aug 5, 2013Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss
Aug 5, 2013J Clin Oncol 2013; 31:3440-1
Zaman Khalil, Thürlimann Beat, Aebi Stefan
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thürlimann B, Senn H, Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24:2206-23.
Aug 4, 2013Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Aug 4, 2013Ann Oncol 2013; 24:2206-23
Goldhirsch A, Winer E P, Coates A S, Gelber R D, Piccart-Gebhart M, Thürlimann Beat, Senn H-J, Panel members
Relative Survival is an Adequate Estimate of Cancer-Specific Survival: Baseline Mortality-Adjusted 10-Year Survival of 771 Rectal Cancer Patients
Tarantino I, Achermann P, Gueller U, Ulrich A, Schmied B, Horber D, Cerny T, Stanga Z, Warschkow R. Relative Survival is an Adequate Estimate of Cancer-Specific Survival: Baseline Mortality-Adjusted 10-Year Survival of 771 Rectal Cancer Patients. Ann Surg Oncol 2013; 20:3877-2884.
Aug 2, 2013Relative Survival is an Adequate Estimate of Cancer-Specific Survival: Baseline Mortality-Adjusted 10-Year Survival of 771 Rectal Cancer Patients
Aug 2, 2013Ann Surg Oncol 2013; 20:3877-2884
Tarantino Ignazio, Achermann Philipp, Gueller Ulrich, Ulrich Alexis, Schmied Bruno, Horber Daniel, Cerny Thomas, Stanga Zeno, Warschkow Rene
Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
Büchel B, Sistonen J, Jörger M, Aebi Y, Schürch S, Largiadèr C. Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients. Clin Chem Lab Med 2013; 51:1681-8.
Aug 1, 2013Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
Aug 1, 2013Clin Chem Lab Med 2013; 51:1681-8
Büchel Barbara, Sistonen Johanna, Jörger Markus, Aebi Yolanda, Schürch Stefan, Largiadèr Carlo R
Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120
Geisthoff U, Nguyen H, Hess D. Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120. Ann Hematol 2013
Jul 27, 2013Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120
Jul 27, 2013Ann Hematol 2013
Geisthoff Urban W, Nguyen Ha-Long P, Hess Dagmar
Optimizing treatment of seminoma stage IIA/B step by step
Papachristofilou A, Cathomas R, Bedke J, Souchon R, Kolb C, Gillessen Sommer S. Optimizing treatment of seminoma stage IIA/B step by step. Ann Oncol 2013; 24:2463.
Jul 17, 2013Optimizing treatment of seminoma stage IIA/B step by step
Jul 17, 2013Ann Oncol 2013; 24:2463
Papachristofilou A, Cathomas R, Bedke J, Souchon R, Kolb C, Gillessen Sommer Silke
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial
Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 2013; 105:1018-26.
Jul 16, 2013Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial
Jul 16, 2013J Natl Cancer Inst 2013; 105:1018-26
Moebus Volker, Untch Michael, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, Nitz Ulrike, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Huober Jens, Schneeweiss Andreas, Jackisch Christian, AGO Breast Study Group
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
Anghel R, Bachmann A, Beksac M, Brodowicz T, Finek J, Komadina R, Krzemieniecki K, Láng I, Marencak J, von Moos R, Pecherstorfer M, Rordorf T, Vrbanec D, Zielinski C, ĀăąĆĉČĎ Ā. Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. Wien Klin Wochenschr 2013; 125:439-47.
Jul 6, 2013Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
Jul 6, 2013Wien Klin Wochenschr 2013; 125:439-47
Anghel Rodica, Bachmann Alexander, Beksac Meral, Brodowicz Thomas, Finek Jindřich, Komadina Radko, Krzemieniecki Krzysztof, Láng István, Marencak Jozef, von Moos Roger, Pecherstorfer Martin, Rordorf Tamara, Vrbanec Damir, Zielinski Christoph C, ĀăąĆĉČĎ Ā ā Ă ă Ą ą Ć ć Ĉ ĉ Ċ ċ Č č Ď ď Đ đ Ē ē Ĕ ĕ Ė ė Ę ę Ě ě Ĝ ĝ Ğ ğ Ġ ġ Ģ ģ Ĥ ĥ Ħ ħ Ĩ ĩ Ī ī Ĭ ĭ Į į İ ı IJ ij Ĵ ĵ Ķ ķ ĸ Ĺ ĺ Ļ ļ Ľ ľ Ŀ ŀ Ł ł Ń ń Ņ ņ Ň ň ʼn Ŋ ŋ Ō ō Ŏ ŏ Ő ő Œ œ Ŕ ŕ Ŗ ŗ Ř ř Ś ś Ŝ ŝ Ş ş Š š Ţ ţ Ť ť Ŧ ŧ Ũ ũ Ū ū Ŭ ŭ Ů ů Ű ű Ų ų Ŵ ŵ Ŷ ŷ Ÿ Ź ź Ż ż Ž ž ſ
Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer
Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D. Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer. Support Care Cancer 2013; 21:3085-93.
Jul 5, 2013Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer
Jul 5, 2013Support Care Cancer 2013; 21:3085-93
Hitz Felicitas, Ribi Karin, Li Qiyu, Klingbiel Dirk, Cerny Thomas, Koeberle Dieter
Management of elderly patients with advanced non-small cell lung cancer: a single-center experience
Früh M, Besrour H, Gillessen Sommer S, Jörger M, Hitz F, Savidan A, Cerny T, Ess S. Management of elderly patients with advanced non-small cell lung cancer: a single-center experience. Chemotherapy 2013; 59:42-50.
Jul 2, 2013Management of elderly patients with advanced non-small cell lung cancer: a single-center experience
Jul 2, 2013Chemotherapy 2013; 59:42-50
Früh Martin, Besrour H, Gillessen Sommer Silke, Jörger Markus, Hitz Felicitas, Savidan A, Cerny Thomas, Ess S
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Sandhu S, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter C, Iannone R, Kaye S, de Bono J, Thway K, Kreischer N, Schelman W, Wilding G, Moreno V, Baird R, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Wenham R. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013; 14:882-92.
Jun 28, 2013The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Jun 28, 2013Lancet Oncol 2013; 14:882-92
Sandhu Shahneen K, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Thway Khin, Kreischer Nathan, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Wenham Robert M
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
Pezaro C, de Bono J, Olmos D, Reid A, Seed G, Bianchini D, Omlin A, Cassidy A, Tunariu N, Mukherji D, Attard G. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer 2013; 109:325-31.
Jun 27, 2013Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
Jun 27, 2013Br J Cancer 2013; 109:325-31
Pezaro C, de Bono J S, Olmos D, Reid A H M, Seed G, Bianchini D, Omlin Aurelius, Cassidy A M, Tunariu N, Mukherji D, Attard G